Shire Announces Judges Panel for New Scholarship Program for Students
Diagnosed with ADHD

PHILADELPHIA--(BUSINESS WIRE)--Shire announces a distinguished panel of judges for their new
scholarship program being offered to students in the United States
diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). The
president of the Attention Deficit Disorder Association (ADDA), the CEO
of Children and Adults with Attention Deficit/Hyperactivity Disorder
(CHADD), and the president of the American Professional Society of ADHD
and Related Disorders (APSARD) are among those who will volunteer their
time and expertise as judges to review the applications and select the
scholarship recipients.

The Shire ADHD Scholarship Program was developed and is being
implemented by Shire, a global specialty biopharmaceutical company that
focuses on helping those diagnosed with ADHD as well as other medical
conditions. This unique program awards a $2,000 scholarship and one year
of prepaid coaching services provided in partnership with the Edge
Foundation, and is part of Shire’s efforts to develop additional
services and opportunities that help support ADHD patients, their
families, and the ADHD community overall. Applications for 2011 will be
accepted through July 7th.

The panel of judges will select the final 25 one-time scholarship
recipients from applications submitted for consideration. For complete
information on Shire’s ADHD Scholarship Program, including eligibility
requirements and the application, visit www.ShireADHDScholarship.com.

“Shire is very appreciative that so many advocates and experts in the
ADHD community have agreed to be part of the judging panel in support of
this scholarship program,” said Michael Yasick, Senior Vice President of
Shire’s ADHD business.

The Judging Panel

Dr. David Baron, MSEd, DO is the immediate past president of the Group
for the Advancement of Psychiatry (GAP) and is currently the
Psychiatrist-in-Chief at the USC University Hospital and Norris Cancer
Hospital and Vice Chair and Residency Training Director at the USC
Department of Psychiatry.

Carol Caruso is the Secretary of the National Alliance of Mental Illness
(NAMI) Board of Directors. She is also the executive director of NAMI
PA, Montgomery County; she has a Master’s Degree in Creative Arts
Therapy from Hahnemann (now Drexel) University. She has worked for
nearly thirty years in various mental health programs for both adults
and children in southeastern Pennsylvania, mostly in Montgomery County.

Evelyn Polk Green is president of the Attention Deficit Disorder
Association (ADDA) a leading advocacy group for adults with ADHD. An
adult with ADHD and the mother of two adult sons diagnosed with ADHD,
Green is a national advocate on behalf of children and adults with
learning differences, ADHD and other mental health issues.

Dr. Ruth Hughes, PhD is CEO of Children and Adults with Attention
Deficit/Hyperactivity Disorder (CHADD), where she has been responsible
for public policy, training, membership and chapter development. A
clinical psychologist and mother of an adult son with ADHD, Dr. Hughes’
work today focuses on advocating for a system of care where everyone
with ADHD has access to state-of-the-art information and services.

Dr. Anthony Rostain, M.D., M.A. is Professor of Psychiatry and
Pediatrics at the University of Pennsylvania School of Medicine. At Penn
Behavioral Health, he is also director of the Adult Development
Disorders Unit, which includes the Adult ADHD Treatment and Research
Program. Dr. Rostain is the incoming President of the American
Professional Society for ADHD and Related Disorders (APSARD)

In addition, two members of Shire’s senior leadership team will join the
panel.

As part of the Shire ADHD Scholarship Program, Shire is partnering with
The Edge Foundation, a leading national nonprofit organization, to
provide coaching services for each student awarded a Shire ADHD
Scholarship. The coaching includes weekly sessions with
specially-trained ADHD coaches who are passionate about their work. The
students set weekly goals and action plans to meet those goals and have
unlimited e-mail and phone support from their coaches to help keep them
on track. This support may be important in the higher education
environment where they are living independently, have more free time and
less adult supervision.

Shire’s ADHD Scholarship Program is part of Shire’s comprehensive
approach centered on putting patients first by offering treatments and
services designed to help patients, parents, advocates and others
providing care for people diagnosed with ADHD. The ADHD Scholarship
Program is expected to be an annual initiative.

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the
specialist physician. Shire focuses its business on attention deficit
hyperactivity disorder (ADHD), human genetic therapies (HGT) and
gastrointestinal (GI) diseases as well as opportunities in other
therapeutic areas to the extent they arise through acquisitions. Shire’s
in-licensing, merger and acquisition efforts are focused on products in
specialist markets with strong intellectual property protection and
global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively
small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995 – will check to see if we need this in the press
release.

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a
number of risks and uncertainties and are subject to change at any time.
In the event such risks or uncertainties materialize, the Company’s
results could be materially adversely affected. The risks and
uncertainties include, but are not limited to, risks associated with:
the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company’s
Specialty Pharmaceutical and Human Genetic Therapies products, as well
as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the
Company’s products; the Company’s ability to manufacture its products in
sufficient quantities to meet demand; the impact of competitive
therapies on the Company’s products; the Company’s ability to register,
maintain and enforce patents and other intellectual property rights
relating to its products; the Company’s ability to obtain and maintain
government and other third-party reimbursement for its products; and
other risks and uncertainties detailed from time to time in the
Company’s filings with the Securities and Exchange Commission.